Literature DB >> 7527131

[Comparison between low and high doses of aprotinin in heart surgery].

M Maccario1, C Fumagalli, R Deangelis, R Delfino, A Pergolo, V Dottori, L Barberis.   

Abstract

High dose aprotinin has been used in cardiac surgery (Royston 1987) to reduce post operative bleeding. A low dose aprotinin ie 2000000 KIU in the oxygenator prime, has been also proposed. OBJECTIVE. To evaluate postoperative losses and holomogous blood transfusions, in patients undergoing cardiac surgery treated with low and high dose aprotinin. METHODS AND MATERIALS. Ninety-nine patients, between January and May 1993, have randomized in 3 groups: A, high dose aprotinin; B, low dose aprotinin; C, control. All patients were treated with additional blood saving techniques routinely used in our center. Statistical analysis was performed by means of ANOVA and Tukey Kramer test. MAIN RESULTS. Five patients (3 in group A, 1 each in groups B and C) have been excluded during the trial. The groups resulted omogeneus and comparable. Total blood losses were 372 +/- 159 ml in group A, 401 +/- 178 ml in group B (difference are not significative); the 621 +/- 255 m1 in group C are highly significative. Patients transfused were 18.7% in group C, 10.34% in group A and 6.20% in group B. CONCLUSIONS. Effects of low dose aprotinin are comparable to high dose. Further advantages with low dose are reduction of collateral effects and intolerance phenomena and a better cost benefits ratio.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527131

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  2 in total

Review 1.  Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Authors:  David A Henry; Paul A Carless; Annette J Moxey; Dianne O'Connell; Barrie J Stokes; Dean A Fergusson; Katharine Ker
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

2.  Low dose aprotinin increases mortality and morbidity in coronary artery bypass surgery(*).

Authors:  Feridoun Sabzi; Gholam Reza Moradi; Heidar Dadkhah; Alireza Poormotaabed; Samsam Dabiri
Journal:  J Res Med Sci       Date:  2012-01       Impact factor: 1.852

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.